|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-2-27
|
|
pubmed:abstractText |
The first choice of treatment for American cutaneous leishmaniasis is the pentavalent antimonial drug. Although it has been shown that this treatment is mostly effective and indicated, some disadvantages should be taken into account such as side effects, long term treatment inconveniences and counter-indication for patients suffering from cardiopathy, nephropathy; yet, aging, pregnancy and other conditions. With the advent of the vaccine anti-American cutaneous leishmaniasis as a prophylactic measure, studies on therapy using the vaccine associated or not with other drugs have been performed by many investigators and it is currently among the alternative treatments and prevention measures for American cutaneous leishmaniasis. In conclusion, the association between antimony and vaccine (immunochemotherapy) showed the same cure rate when compared with the standard treatment (100%) and it was also able to reduce the salt volume in 17.9% and treatment length from 87 to 62 days, decreasing side effects.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0037-8682
|
|
pubmed:author |
pubmed-author:BatistaSebastião MarianoSM,
pubmed-author:BotelhoAna Cristina de CarvalhoAC,
pubmed-author:CaiaffaWaleska TeixeiraWT,
pubmed-author:CostaCarlos Alberto daCA,
pubmed-author:DiasMagnoM,
pubmed-author:GenaroOdairO,
pubmed-author:LimaAntonio de OliveiraAde O,
pubmed-author:Machado-CoelhoGeorge Luiz LinsGL,
pubmed-author:MagalhãesPaulo AraújoPA,
pubmed-author:MayrinkWilsonW,
pubmed-author:MeloMaria Norma deMN,
pubmed-author:MichalickMarilene Susan MarquesMS,
pubmed-author:NascimentoEvaldo doE,
pubmed-author:WilliamsPaulP
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
39
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
14-21
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16501760-Adolescent,
pubmed-meshheading:16501760-Adult,
pubmed-meshheading:16501760-Aged,
pubmed-meshheading:16501760-Aged, 80 and over,
pubmed-meshheading:16501760-Animals,
pubmed-meshheading:16501760-Antiprotozoal Agents,
pubmed-meshheading:16501760-BCG Vaccine,
pubmed-meshheading:16501760-Child,
pubmed-meshheading:16501760-Child, Preschool,
pubmed-meshheading:16501760-Drug Therapy, Combination,
pubmed-meshheading:16501760-Female,
pubmed-meshheading:16501760-Humans,
pubmed-meshheading:16501760-Immunotherapy,
pubmed-meshheading:16501760-Leishmania,
pubmed-meshheading:16501760-Leishmaniasis, Cutaneous,
pubmed-meshheading:16501760-Male,
pubmed-meshheading:16501760-Meglumine,
pubmed-meshheading:16501760-Middle Aged,
pubmed-meshheading:16501760-Organometallic Compounds,
pubmed-meshheading:16501760-Protozoan Vaccines,
pubmed-meshheading:16501760-Time Factors,
pubmed-meshheading:16501760-Treatment Outcome
|
|
pubmed:articleTitle |
Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment.
|
|
pubmed:affiliation |
Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. wilsonmayrink@uol.com.br
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
